Search results
Results from the WOW.Com Content Network
The Stop TB Initiative was established following the meeting of the First Session of the Ad Hoc Committee on the Tuberculosis Epidemic held in London in March 1998. [4] In March 2000 the Stop TB Partnership produced the Amsterdam Declaration to Stop TB, which called for action from ministerial delegations of 20 countries with the highest burden of TB.
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB.. The medical standard for active TB is a short course treatment involving a combination of isoniazid, rifampicin (also known as Rifampin), pyrazinamide, and ethambutol for the first two months.
Extrapulmonary tuberculosis is tuberculosis (TB) within a location in the body other than the lungs. It accounts for an increasing fraction of active cases, from 20 to 40% according to published reports, [2] and causes other kinds of TB. [3] [4] These are collectively denoted as "extrapulmonary tuberculosis". [4]
Drug-resistant TB is a serious public health issue in many developing countries, as its treatment is longer and requires more expensive drugs. MDR-TB is defined as resistance to the two most effective first-line TB drugs: rifampicin and isoniazid.
Tuberculosis creates cavities visible in x-rays like this one in the patient's right upper lobe.. A posterior-anterior (PA) chest X-ray is the standard view used; other views (lateral or lordotic) or CT scans may be necessary.
Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection caused by bacteria that are resistant to treatment with at least two of the most powerful first-line anti-TB medications (drugs): isoniazid and rifampicin. Some forms of TB are also resistant to second-line medications, and are called extensively drug-resistant TB .
TB Alliance (formally The Global Alliance for TB Drug Development) is a not-for-profit product development partnership (PDP) dedicated to the discovery and development of new, faster-acting and affordable tuberculosis (TB) medicines.
Mycobacterium tuberculosis is the most common cause of both pulmonary tuberculosis and tuberculous lymphadenitis. [1] [6] Historically, transmission of Mycobacterium bovis from dairy consumption was another frequent cause of tuberculous lymphadenitis, but incidence has drastically decreased in developed countries since the advent of pasteurization and other efforts to prevent bovine ...